Elanco (NYSE: ELAN) CFO receives new deferred stock unit grant

Rhea-AI Filing Summary

VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.

Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 7.6217 deferred stock units at a reference price of $24.98 per unit. This award increases his directly held deferred stock units to 31.0919. Each unit represents the right to receive one share of Elanco common stock or the cash equivalent, settling after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VanHimbergen Robert M

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Stock Units	(1)	02/20/2026		A		7.6217		(2)	(2)	Common Stock	7.6217	$24.98	31.0919	D

Explanation of Responses:

1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.

2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Robert M. VanHimbergen	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Elanco (ELAN) report for Robert M. VanHimbergen?

Elanco reported that EVP and CFO Robert M. VanHimbergen received 7.6217 deferred stock units. These units were granted at a reference price of $24.98 each, increasing his directly held deferred stock units to 31.0919 under the company’s long-term incentive framework.

What are deferred stock units in the Elanco (ELAN) executive plan?

Each Elanco deferred stock unit represents the right to receive one share of company common stock or the cash equivalent. These units function as a form of long-term compensation that tracks share value but typically do not pay out until a future settlement event.

When will Robert M. VanHimbergen’s Elanco (ELAN) deferred stock units settle?

The deferred stock units settle in cash or Elanco common stock following termination of employment or during a specified future year. Settlement timing follows the terms of Elanco’s Executive Deferral and Stock Match Plan governing these awards.

How many deferred stock units does the Elanco (ELAN) CFO hold after this grant?

After the latest grant, Elanco’s EVP and CFO Robert M. VanHimbergen directly holds 31.0919 deferred stock units. This reflects the addition of 7.6217 units awarded at a reference price of $24.98 per unit as part of his compensation.

Does the Elanco (ELAN) deferred stock unit grant involve an open-market buy or sell?

The reported Elanco transaction is a grant of deferred stock units, not an open-market purchase or sale. It is categorized as a grant, award, or other acquisition issued as part of the company’s executive compensation arrangements.